BRIEF — Liquidia Announces Global Settlement Resolving All Pending Litigation With United Therapeutics, Ensuring Continued Commercialization Of Yutrepia In Pah

Liquidia Corporation: Liquidia Announces Global Settlement Resolving All Pending Litigation With United Therapeutics, Ensuring Continued Commercialization Of Yutrepia In Pah Liquidia Corporation - Settlement Fully Resolves Six Ongoing Lawsuits Between Liquidia And United Therapeutics Liquidia Corporation - To Pay Net $380.70 Million In Installments In 2026 And 2027 Liquidia Corporation - To Pay $175 Million To United Therapeutics Within 30 Business Days Liquidia Corporation - Terminates Promotional Agreement For Treprostinil Injection Liquidia Corporation - Yutrepia Remains Available To Pah Patients Without Disruption Liquidia Corporation - Removes Ph-ild Indication From Yutrepia Label And Ceases Promotion Source text:... Further company coverage: LQDA.O